1-5 of 5
Erwin R. Boghaert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis

Sha Jin, Dan Cojocari, Julie J. Purkal, Relja Popovic, Nari N. Talaty, Yu Xiao, Larry R. Solomon, Erwin R. Boghaert, Joel D. Leverson, Darren C. Phillips
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (13): 3371–3383.
https://doi.org/10.1158/1078-0432.CCR-19-1900
Published: 01 July 2020
View article titled, 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis
Open the PDF for 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis in another window
Includes: Supplementary data
Journal Articles

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET–Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

Jieyi Wang, Mark G. Anderson, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Lora Tucker, Qian Zhang, Edward K. Han, Joann P. Palma, Louie Naumovski, Edward B. Reilly
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 992–1000.
https://doi.org/10.1158/1078-0432.CCR-16-1568
Published: 14 February 2017
View article titled, ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both <em>MET</em>–Amplified and c-Met–Overexpressing Tumors, Irrespective of <em>MET</em> Pathway Dependence
Open the PDF for ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both <em>MET</em>–Amplified and c-Met–Overexpressing Tumors, Irrespective of <em>MET</em> Pathway Dependence in another window
Includes: Supplementary data
Journal Articles

Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma

John F. DiJoseph, Maureen M. Dougher, Lyka B. Kalyandrug, Douglas C. Armellino, Erwin R. Boghaert, Philip R. Hamann, Justin K. Moran, Nitin K. Damle
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 242–249.
https://doi.org/10.1158/1078-0432.CCR-05-1905
Published: 05 January 2006
View article titled, Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma
Open the PDF for Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma in another window
Journal Articles

Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma

John F. DiJoseph, Mary E. Goad, Maureen M. Dougher, Erwin R. Boghaert, Arthur Kunz, Philip R. Hamann, Nitin K. Damle
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (24): 8620–8629.
https://doi.org/10.1158/1078-0432.CCR-04-1134
Published: 28 December 2004
View article titled, Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma
Open the PDF for Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma in another window
Journal Articles

Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193- N -Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts

Erwin R. Boghaert, Latha Sridharan, Douglas C. Armellino, Kiran M. Khandke, John F. DiJoseph, Arthur Kunz, Maureen M. Dougher, Fan Jiang, Lyka B. Kalyandrug, Philip R. Hamann, Philip Frost, Nitin K. Damle
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4538–4549.
https://doi.org/10.1158/1078-0432.CCR-04-0037
Published: 06 July 2004
View article titled, Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193- <em>N</em> -Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewis<sup>y</sup> and Eliminates Lewis<sup>y</sup>-Positive Human Carcinoma Cells and Xenografts
Open the PDF for Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193- <em>N</em> -Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewis<sup>y</sup> and Eliminates Lewis<sup>y</sup>-Positive Human Carcinoma Cells and Xenografts in another window